We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Vertex (VRTX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Vertex Pharmaceuticals (VRTX - Free Report) will report quarterly earnings of $5.07 per share in its upcoming release, pointing to a year-over-year increase of 27.4%. It is anticipated that revenues will amount to $3.17 billion, exhibiting an increase of 8.8% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Vertex metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts predict that the 'Revenues by Product- Trikafta/Kaftrio' will reach $2.57 billion. The estimate indicates a change of -5.6% from the prior-year quarter.
The consensus estimate for 'Revenues by Product- Other product revenues' stands at $216.84 million. The estimate suggests a change of +13.4% year over year.
Analysts expect 'Geographic Revenues- United States' to come in at $1.87 billion. The estimate indicates a year-over-year change of +1.9%.
Based on the collective assessment of analysts, 'Geographic Revenues- Outside of the United States' should arrive at $1.25 billion. The estimate indicates a year-over-year change of +16.3%.
Vertex shares have witnessed a change of +3% in the past month, in contrast to the Zacks S&P 500 composite's -0.2% move. With a Zacks Rank #3 (Hold), VRTX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Seeking Clues to Vertex (VRTX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts forecast that Vertex Pharmaceuticals (VRTX - Free Report) will report quarterly earnings of $5.07 per share in its upcoming release, pointing to a year-over-year increase of 27.4%. It is anticipated that revenues will amount to $3.17 billion, exhibiting an increase of 8.8% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Vertex metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts predict that the 'Revenues by Product- Trikafta/Kaftrio' will reach $2.57 billion. The estimate indicates a change of -5.6% from the prior-year quarter.
The consensus estimate for 'Revenues by Product- Other product revenues' stands at $216.84 million. The estimate suggests a change of +13.4% year over year.
Analysts expect 'Geographic Revenues- United States' to come in at $1.87 billion. The estimate indicates a year-over-year change of +1.9%.
Based on the collective assessment of analysts, 'Geographic Revenues- Outside of the United States' should arrive at $1.25 billion. The estimate indicates a year-over-year change of +16.3%.
View all Key Company Metrics for Vertex here>>>Vertex shares have witnessed a change of +3% in the past month, in contrast to the Zacks S&P 500 composite's -0.2% move. With a Zacks Rank #3 (Hold), VRTX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .